Annexon shares surge 10.18% intraday after Cantor Fitzgerald reiterates overweight rating and highlights 2026 pipeline milestones.

Annexon surged 10.18% intraday after Cantor Fitzgerald reiterated its Overweight rating and the company completed a $86.25 million public offering. The broker’s reaffirmed recommendation, coupled with the capital raise, signaled strong investor confidence in Annexon’s pipeline advancements, including late-stage therapies for geographic atrophy and Guillain-Barré Syndrome. These developments, highlighted in presentations at the 2026 J.P. Morgan Healthcare Conference, underscored the company’s potential for significant value creation through pivotal trials and regulatory submissions. Institutional buying and positive analyst sentiment further reinforced the upward momentum, aligning with the stock’s sharp intraday increase.